Abstract 1729P
Background
MDTs are a central institution of decision making in oncological centres. Good recommendations are comprehensible, follow guidelines, are consistent to following treatment and responsibility for this case must be made explicit. In order to constantly improve our performance, we examined key factors influencing MDT recommendations. After this analysis, structural intervention was performed to exclude the main factors influencing our performance negatively. Here we report the outcomes and results of this intervention.
Methods
After examining our MDT performance retrospectively in 488 tumor board decisions, we changed the registration process, including definition of required input for aspects of patient history and the protocol of our MDT for GI cancers. We also made sure that personal responsibility was provided for case presentation as well as for further action. Analysis of MDT recommendation after this intervention was performed using the same questionnaire as in the first analysis prospectively in 488 tumor board presentations and decisions of the complete following year. We correlated input-factors of MDT registration to output-factors defining reasonable MDT recommendations. Simple comparison was performed using chi-square testing between individual factors, group of factors and outcome variables.
Results
Following our intervention, we measured significant increase of all factors considered to be most influential for good recommendations (Table).
Table: 1729P
Input factor | Before (%) | After (%) | p-value |
Presence of core team members | 54,7 | 62,8 | < .0001 |
Clear indications of patient wishes | 85,96 | 96,93 | < .0001 |
Complete case information | 80,12 | 89,55 | < .0001 |
Information of thorough discussion | 5,7 | 17,2 | .095 |
Good recommendations | 65,16 | 84,63 | < .0001 |
Conclusions
Oncological treatment is often based on MDT recommendations. Therefore, high quality of MDT must be ensured, transparency and understandability of the protocol must be clear and responsibility for further action needs to be addressed. We hereby demonstrate that changing infrastructural factors in registration and protocol of recommendations lead to improved tumor board decisions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Galonska.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23